pneumonia may increase the risk of developing multiple sclerosis.

31. Lehmann-Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. ;6:-

Muscle weakness and fatigue are common symptoms in multiple sclerosis (MS).

From December 2008 through June 2013, a total of 236 participants were screened, and 143 underwent randomization from January 2009 through July 2013 (). One participant underwent randomization in error, having met the multiple sclerosis outcome before the time of randomization. The intention-to-treat analysis included 142 participants: 72 in the minocycline group and 70 in the placebo group. The placebo group included significantly more participants whose symptom onset was in the spinal cord (P=0.04) and significantly more participants who had more than one enhancing lesion on MRI at baseline (P=0.04). The characteristics of the participants at baseline were otherwise similar in the two study groups (, and Table S3 in the ).

40. Bar-Or A. The immunology of multiple sclerosis. ;28:-

The treatment did not reduce disease activity,disability, or fatigue and did not improve quality of life.

Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study.
Multiple Sclerosis.

Cognitive impairment in multiple sclerosis - ScienceDirect

22. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. ;13:-

Clemastine fumarate as a remyelinating ..

21. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. ;11:-

Aspartame is a low calorie sweetener

The numerical imbalance in the neoplasms observed in the OPERA I trial and in the ORATORIO trial, which involved patients with primary progressive multiple sclerosis, warrants ongoing evaluation in the context of the epidemiology of neoplasm in the population of patients with multiple sclerosis and long-term experience with ocrelizumab and other anti-CD20 treatments. No cases of progressive multifocal leukoencephalopathy (PML) have been reported so far with ocrelizumab across all clinical studies (F. Hoffman–La Roche data on file). Further long-term assessment of the safety profile of ocrelizumab is required in order to fully characterize the risk of uncommon adverse events, including PML.

Multiple Sclerosis and 'Cog Fog': Clearing My Mind

Inflammation and neurodegeneration are understood to be two distinct but overlapping mechanisms of the pathogenesis of multiple sclerosis, with inflammation dominating the early stages of disease. The use of current therapies in patients with relapsing multiple sclerosis has been associated with an improved overall prognosis, as compared with the pretreatment era. However, most treated patients still have worsening neurologic disability over time in this lifelong disease. Additional and extended studies will be required in order to determine whether the outcomes observed in these 96-week trials, including a near-complete cessation of new plaque formation as assessed by MRI of the brain, translate into enhanced protection against accrual of disability over the long term.

Turmeric May Fight Multiple Sclerosis

I had no members of my family have a history of multiple sclerosis; I was diagnosed in April of 2009. I drank so many diet dr peppers throughout the day, enough to accumulate 100 pounds of aluminum every couple months (I recycle). I am a very health-concious person and have wondered, since april, why? When I was first diagnosed, a friend told me about the diet drinks I drank so much but wasn't knowledgable enough to elaborate. I was concerned; so, I looked up phenylalanine, which was a warning on the back. I got no results of toxicity for this, ironically, but now, months later, I type in aspartame and my question of "why" is answered. The headaches started in september of 2008, they continued until I lost sensation on my entire face (in april), and then I went blind in my right eye in July.